In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will the Mid-Sized European Rx Company Survive?

Executive Summary

Given the costs and scientific requirements of the international drug business, mid-sized European companies should restructure themselves as NRDOs (No Research, Development Only companies), partnering for new products with biotech companies, says Fred Frank of Lehman Brothers.

You may also be interested in...



US FDA’s Proposed Sunscreen Order Due In Days With Inquiry Ongoing Re Environmental Impacts

Industry anticipates a proposed administrative order from the US FDA by 27 September on OTC sunscreen drug products, including GRASE status of active ingredients. Meanwhile, the agency’s probe continues into UV filter environmental impacts, and the National Academy of Sciences is gathering information to weigh those possible ills against human health consequences of reduced sunscreen use.

Paying For Gene Therapy: Biggest Cost Challenges Two To Three Years Away?

Only about one-quarter of the 40 gene therapies projected to launch by the end of 2025 would have potential US patient populations of more than 50,000. But a handful of treatments could target millions of individuals.

QUOTED. Frank Pasquale.

With the era of medical automation upon us, surgeons are increasingly turning to robots and artificial intelligence for better results in the operating suite. See what Frank Pasquale, professor at Brooklyn Law School and author of the book New Laws of Robotics: Defending Human Expertise in the Age of AI, said about it here.

Topics

UsernamePublicRestriction

Register

IV000221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel